- Krystal Biotech reported Q3 revenue of $127.3 million. The biotech firm's top line is driven by Vyjuvek sales. No earnings per share or prior-period comparison was included in the initial release.
Krystal Biotech reported Q3 revenue of $127.3 million. The biotech firm's top line is driven by Vyjuvek sales. No earnings per share or prior-period comparison was included in the initial release.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.